Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
41.06
-0.69 (-1.65%)
Sep 24, 2025, 3:59 PM EDT
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B CHF
Revenue Growth
+4.80%
P/S Ratio
3.59
Revenue / Employee
614.90K CHF
Employees
103,249
Market Cap
286.93B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 2.12M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Roche Holding AG News
- 20 hours ago - Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025 - GlobeNewsWire
- 20 hours ago - Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025 - Business Wire
- 1 day ago - Roche's Giredestrant: A Ray Of Hope On A Cloudy Horizon? - Seeking Alpha
- 2 days ago - Roche Holding AG - Special Call - Seeking Alpha
- 2 days ago - Roche Targets Top Spot In Weight Loss Drug Market - Benzinga
- 2 days ago - Roche Targets Top Spot In Weight Loss Drug Market - Benzinga
- 2 days ago - Roche (RHHBY) Reports Positive Trial Results for Breast Cancer Drug Portfolio - GuruFocus
- 2 days ago - Roche moves obesity asset CT-388 into phase 3 - Seeking Alpha